 REDWOOD CITY, Calif., Aug. 23, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverums president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the companys product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA, the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU. 